The customer is the US Department of Health and Human Services (HHS).
This order takes the HHS orders to date to more than 40m vaccine doses, with a total cumulative contract value of approximately USD453m.
The FDA-approved vaccine is indicated for the active immunisation, by intranasal administration, of individuals aged two to 49 years against influenza caused by pandemic (H1N1) 2009 virus.
MedImmune is the worldwide biologics business for AstraZeneca plc (LSE:AZN.L) (NYSE:AZN).
Comments on this story may be sent to admin@m2.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index